Cargando…

Retinal Morpho-Functional Changes Following 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Chronic Diabetic Macular Edema

PURPOSE: To evaluate morpho-functional outcomes of the intravitreal fluocinolone acetonide (FAc) implant. METHODS: Retrospective, observational, single-center study. Primary endpoint was the mean change in central macular thickness (CMT) from baseline to month 1–3. Secondary endpoints included mean...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minnella, Angelo Maria, Picardi, Stefano Maria, Maceroni, Martina, Albanesi, Francesca, De Siena, Elisa, Placidi, Giorgio, Caputo, Carmela Grazia, De Vico, Umberto, Rizzo, Stanislao, Falsini, Benedetto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096132/ https://www.ncbi.nlm.nih.gov/pubmed/33948926 http://dx.doi.org/10.1007/s12325-021-01751-5

Ejemplares similares

Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Combined Intravitreal Dexamethasone Implant and Cataract Surgery in Patients with Diabetic Retinopathy: Effect on Retinal Morphology and Function
por: Minnella, Angelo Maria, et al.
Publicado: (2020)

Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis
por: Hikal, Muaas, et al.
Publicado: (2021)

Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema
por: Weber, Lea F., et al.
Publicado: (2019)

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema
por: Kessler, Lucy Joanne, et al.
Publicado: (2022)

Correction to: Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2020)

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
por: Messenger, Wyatt B, et al.
Publicado: (2013)

Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review
por: Ribeiro, Flávio, et al.
Publicado: (2021)

USH2A-Related Retinitis Pigmentosa: Staging of Disease Severity and Morpho-Functional Studies
por: Falsini, Benedetto, et al.
Publicado: (2021)

Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant – A Case Report
por: Meira, Jorge, et al.
Publicado: (2019)

Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy
por: Lima-Fontes, Mário, et al.
Publicado: (2022)

Ocular Morpho-Functional Evaluation in ATTRv Pre-Symptomatic Carriers: A Case Series
por: Maceroni, Martina, et al.
Publicado: (2023)

Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine–Gass Syndrome
por: Marques, João Heitor, et al.
Publicado: (2021)

Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic macular edema
por: Coney, Joseph M
Publicado: (2019)

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
por: Coelho, João, et al.
Publicado: (2019)

Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve
por: Kessler, Lucy Joanne, et al.
Publicado: (2023)

Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
por: Baillif, Stéphanie, et al.
Publicado: (2022)

Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema
por: Byun, Matthew, et al.
Publicado: (2020)

Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months
por: Moll-Udina, Aina, et al.
Publicado: (2023)

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN(®))
por: Pessoa, Bernardete, et al.
Publicado: (2020)

Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration
por: Lynch, Stephanie K., et al.
Publicado: (2019)

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant
por: Bertelmann, Thomas, et al.
Publicado: (2015)

Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
por: McCluskey, Jessica D, et al.
Publicado: (2019)

Efficacy of 0.19 mg Fluocinolone Acetonide Implant in Non-infectious Posterior Uveitis Evaluated as Area Under the Curve
por: Battista, Marco, et al.
Publicado: (2021)

Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis
por: Park, Jong G., et al.
Publicado: (2020)

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Bilateral 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the Successful Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Secondary Macular Oedema: A Case Report and Review of Intravitreal Therapies
por: Ansari, Abdus Samad, et al.
Publicado: (2021)

Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
por: Haritoglou, Christos, et al.
Publicado: (2013)

Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE
por: Elbarky, Ahmed Mohammed
Publicado: (2020)

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema
por: Singh, P, et al.
Publicado: (2018)

Optical Coherence Tomography Biomarkers of Inflammation in Diabetic Macular Edema Treated by Fluocinolone Acetonide Intravitreal Drug-Delivery System Implant
por: Arrigo, Alessandro, et al.
Publicado: (2020)

Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study
por: Buhl, Lara, et al.
Publicado: (2022)

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
por: Massa, Horace, et al.
Publicado: (2018)

Sustained Control of Serpiginous Choroiditis with the Fluocinolone Acetonide 0.18 mg Intravitreal Implant
por: Siddiqui, Yousuf, et al.
Publicado: (2022)

Clinical utility of intravitreal fluocinolone acetonide (Iluvien(®)) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
por: Saedon, Habiba, et al.
Publicado: (2017)

Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study
por: Mathis, Thibaud, et al.
Publicado: (2022)

Scleral fixation of fluocinolone acetonide implant()
por: Tabandeh, Homayoun, et al.
Publicado: (2020)

Fluocinolone acetonide intravitreal sustained release device – a new addition to the armamentarium of uveitic management
por: Brumm, Matthew V, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_u2kkifc29a59fgodfic3v7cmmj